The European Medicines Agency will review drugs similar to Vioxx after Merck withdrew it due to increased stroke and heart attack risks.
Vioxx, a COX-2 inhibitor, generated $2.5 billion in sales in 2003.
Merck faces lawsuits over Vioxx-related heart attacks.
The FDA will study other drugs in the same class.
Celebrex, another drug in this class, has robust data.
Vioxx's withdrawal led to a significant financial impact on Merck.
The company knew about Vioxx's risks but continued marketing it.
Lawsuits against Merck are expected to increase.
The FDA criticized
